KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardlytics (CDLX) Current Deferred Revenue (2017 - 2025)

Cardlytics (CDLX) has disclosed Current Deferred Revenue for 9 consecutive years, with $2.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Current Deferred Revenue rose 20.19% year-over-year to $2.6 million, compared with a TTM value of $2.6 million through Dec 2025, up 20.19%, and an annual FY2025 reading of $2.6 million, up 20.19% over the prior year.
  • Current Deferred Revenue was $2.6 million for Q4 2025 at Cardlytics, up from $412000.0 in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $3.3 million in Q3 2023 and bottomed at $259000.0 in Q1 2021.
  • Average Current Deferred Revenue over 5 years is $2.2 million, with a median of $2.3 million recorded in 2023.
  • The sharpest move saw Current Deferred Revenue surged 1105.41% in 2022, then crashed 80.03% in 2025.
  • Year by year, Current Deferred Revenue stood at $3.3 million in 2021, then tumbled by 46.62% to $1.8 million in 2022, then surged by 37.35% to $2.4 million in 2023, then dropped by 10.44% to $2.2 million in 2024, then rose by 20.19% to $2.6 million in 2025.
  • Business Quant data shows Current Deferred Revenue for CDLX at $2.6 million in Q4 2025, $412000.0 in Q3 2025, and $3.1 million in Q2 2025.